Forefront Analytics LLC Invests $557,000 in Edwards Lifesciences Corporation $EW

Forefront Analytics LLC purchased a new position in Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, HoldingsChannel reports. The fund purchased 6,158 shares of the medical research company’s stock, valued at approximately $557,000. Edwards Lifesciences comprises 0.6% of Forefront Analytics LLC’s portfolio, making the stock its 14th biggest holding.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in Edwards Lifesciences during the second quarter worth $5,318,092,000. State Street Corp raised its stake in shares of Edwards Lifesciences by 1.5% during the 4th quarter. State Street Corp now owns 25,991,524 shares of the medical research company’s stock worth $2,215,777,000 after buying an additional 371,892 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Edwards Lifesciences by 4.8% during the 4th quarter. Wellington Management Group LLP now owns 21,793,949 shares of the medical research company’s stock worth $1,857,934,000 after buying an additional 989,533 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Edwards Lifesciences during the 2nd quarter worth $1,274,082,000. Finally, Norges Bank purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth about $803,686,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on EW. Citigroup increased their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Royal Bank Of Canada lifted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their target price for the company from $87.00 to $101.00 in a research note on Friday, July 24th. Mizuho raised their price target on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. Finally, Evercore restated an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. Seventeen equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $100.27.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 23,145 shares of the company’s stock in a transaction dated Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the sale, the vice president owned 98,611 shares of the company’s stock, valued at $8,521,962.62. This represents a 19.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 25,570 shares of company stock valued at $2,219,390. Company insiders own 0.31% of the company’s stock.

Edwards Lifesciences Price Performance

EW stock opened at $89.89 on Monday. The stock has a 50-day moving average price of $89.21 and a two-hundred day moving average price of $84.68. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The company has a market cap of $51.76 billion, a PE ratio of 51.66, a price-to-earnings-growth ratio of 2.25 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. During the same period in the previous year, the company posted $0.67 earnings per share. Edwards Lifesciences’s revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.